Document Detail


New molecular insights into peripheral T cell lymphomas.
MedLine Citation:
PMID:  23023716     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Peripheral T cell lymphomas (PTCLs) are heterogeneous neoplasms and represent about 12% of all lymphoid malignancies. They are often regarded as "orphan diseases," a designation that does not reflect their real incidence but rather signifies the difficulties encountered in their classification, diagnosis, and treatment. Here we revise the current understanding of the pathobiological characteristics of the most common nodal PTCLs by focusing on the contribution given by high-throughput technologies and the identification of potential therapeutic targets proposed by translational studies.
Authors:
Stefano A Pileri; Pier Paolo Piccaluga
Related Documents :
24174826 - Mast cell stabilization potential of sitopaladi churna: an ayurvedic formulation.
24333096 - Immunology of cancer stem cells in solid tumours. a review.
24446786 - The natural killer-activating receptor, nkg2d, on cd3+cd8+ t cells plays a critical rol...
23166016 - 2-(trimethylammonium)ethyl (r)-3-methoxy-3-oxo-2-stearamidopropyl phosphate promotes me...
1865026 - Equine cutaneous mastocytoma: morphology, biological behaviour and evolution of the les...
14527326 - Dynamics of cell surface molecules during t cell recognition.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-10-01
Journal Detail:
Title:  The Journal of clinical investigation     Volume:  122     ISSN:  1558-8238     ISO Abbreviation:  J. Clin. Invest.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-01     Completed Date:  2013-02-01     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  7802877     Medline TA:  J Clin Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3448-55     Citation Subset:  AIM; IM    
Affiliation:
Hematopathology Section, Department of Hematology and Oncology L. and A. Seràgnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. stefano.pileri@unibo.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / therapeutic use
Antibodies, Monoclonal / immunology
Antigens, Neoplasm / immunology
Antigens, Surface / immunology
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Histone Deacetylase Inhibitors / therapeutic use
Humans
Lymphoma, T-Cell, Peripheral / classification,  genetics*,  pathology,  physiopathology
MicroRNAs / genetics,  physiology
Molecular Targeted Therapy
Neoplasm Proteins / antagonists & inhibitors,  genetics*,  physiology
Neoplastic Stem Cells / pathology
Platelet-Derived Growth Factor / physiology
Prognosis
Protein Kinase Inhibitors / therapeutic use
Receptors, Platelet-Derived Growth Factor / physiology
Signal Transduction / genetics,  physiology
T-Lymphocyte Subsets / pathology
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antigens, Neoplasm; 0/Antigens, Surface; 0/Histone Deacetylase Inhibitors; 0/MicroRNAs; 0/Neoplasm Proteins; 0/Platelet-Derived Growth Factor; 0/Protein Kinase Inhibitors; EC 2.7.10.1/Receptors, Platelet-Derived Growth Factor
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hodgkin lymphoma.
Next Document:  Molecular pathogenesis of multiple myeloma and its premalignant precursor.